Ozari Health Opens Low‑Cost Telehealth Platform for Compounded Semaglutide and Tirzepatide
Posted by vik595 in Research & News - 1 points, 0 comments.
This press release says Ozari Health is offering a telehealth service that can prescribe compounded semaglutide and tirzepatide for as little as $86 a month. The company claims a streamlined workflow from a licensed provider to a compounding pharmacy.
To me the headline feels like a double‑edged sword. The price is attractive for people who want a GLP‑1 peptide but can’t afford the brand‑name drugs. On the other hand, compoundedumerous compounds lack the FDA’s rigorous testing and quality controls. In my own protocol I’ve used semaglutide through a licensed provider and have kept close bloodwork and monitoring. Bypassing that can expose patients to unknown potency, contamination, or incorrect dosing. The rollout also raises a regulatory flag: telehealth platforms may not be subject to the same oversight as specialty clinics, and I worry about inadvertent over‑prescribing or lack of dose titration.
Do you think the lower cost will improve access or will it create a market for people to get peptides without proper medical guidance?
Community discussion - research and educational context only. Not medical advice.